Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Safety Issues Prompt Lilly and BMS to Stop Enrollment into Phase III NSCLC Necitumumab Trial

Study will continue, though, as thromboembolic risks appear lower after two cycles of therapy.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll